Galectin Therapeutics Inc.
DE ˙ DB ˙ US3632252025
1,88 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:PHPN / Galectin Therapeutics Inc.
InstitutionRetirement Guys Formula Llc
Latest Disclosed Ownership187,062 shares
Latest Disclosed Value $ 521,903
Retirement Guys Formula Llc reports 1.35% increase in ownership of PHPN / Galectin Therapeutics Inc.

On April 22, 2026 - Retirement Guys Formula Llc filed a 13F-HR form disclosing ownership of 187,062 shares of Galectin Therapeutics Inc. (DE:PHPN) valued at $419,019 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 23, 2026 disclosing 184,562 shares of Galectin Therapeutics Inc.. This represents a change in shares of 1.35% during the quarter. The current value of the position is $351,677 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-22 2026-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 187,062 2,500 1.35 522 -32.07 0.2400
2026-01-23 2025-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 184,562 18,569 11.19 768 9.26 0.3501
2025-10-21 2025-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 165,993 6,400 4.01 703 108.93 0.2473
2025-07-15 2025-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 159,593 4,250 2.74 337 77.78 0.1279
2025-04-23 2025-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 155,343 0 0.00 190 -5.50 0.0942
2025-01-29 2024-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 155,343 91,526 143.42 200 14.29 0.1011
2024-10-21 2024-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 63,817 22,660 55.06 175 88.17 0.0816
2024-08-01 2024-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 41,157 7,425 22.01 93 16.25 0.0446
2024-04-19 2024-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 33,732 12,232 56.89 81 128.57 0.0393
2024-01-22 2023-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 21,500 10,000 86.96 36 59.09 0.0191
2023-10-13 2023-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 11,500 11,500 22 0.0154
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.